Das erste Kondom das eine erektion verursacht = Blockbuster - 500 Beiträge pro Seite

[BrauchGeld]

Ich bin jetzt müde in den nächsten Tagen folgt mehr !

Ich bin vor ein paar Tagen eingestiegen (10000st) und ein Arbeitskollege hat sich gestern in F 5000st gekauft .


Blockbuster Potential für CSD500 das erste Kondom das zusätzlich bei der erektion hilft !!!

Partner für CSD500 ist kein geringerer als SSL (Durex)und das Produkt ist in Europa sogut wie schon Zugelassen anfang 2010 soll es erhältlich sein .

Es sind auch weitere Partnerschaften für dieses Jahr noch geplant um Cashbestand zu verbessern deshalb soll auch keine KE stattfinden .



Futura Medical (FUM.L)

Marktkap : 15 M GBP = 17,6 M €
Kurs : 23,5 p

10 June 2009
AGM Statement


Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, will hold its Annual General Meeting in London later today.

At the meeting, Dr William Potter, the Company's Chairman, will make the following statement:

"The year to date has started well and we are pleased with progress across our portfolio of product opportunities. As outlined in our 2008 Annual Report, we expect marketing authorisation for CSD500 around the end of the current year with the product's launch by SSL International plc as a Durex®-branded condom thereafter.

"I am delighted to say that SSL endorsed our confidence in the commercial potential of CSD500 with a quote in our Annual Report stating: 'We are committed to launching CSD500 as soon as possible and believe it will become a leading product in the Durex® portfolio.'

"We are also in various stages of commercial discussions with marketing partners for three of our other pipeline products, TPR100, PET500 and RAD100. The latter is the most recent addition to our portfolio and has already shown promising in vitro results in the provision of local anaesthesia prior to injections.

"We look forward to updating the market in the near future on these commercial discussions, and on other progress at the Company during the remainder of the year. We view the year ahead, and beyond, with confidence."

[pardon]

Antwort auf Beitrag Nr.: 37.376.960 von BrauchGeld am 11.06.09 23:03:58

Ja da schau her. Man lernt ja nie aus:

das erste Kondom das zusätzlich bei der erektion hilft

War es nicht bisher eher so, daß man ein Kondom dann überzog, wenn man schon eine Erektion hatte?

[HarteNuss]

Antwort auf Beitrag Nr.: 37.376.960 von BrauchGeld am 11.06.09 23:03:58

Hallo,

ich kann schon verstehen, dass Du jetzt müde bist. Wie viele von den 10000 Stück hast Du schon verbraucht
Ich habe Mal ausgerechnet: Wenn Du jeden Tag eines verbrauchst, dann sind die 10000 Stück erst in etwa 27 Jahren weg


Gruß,
Harte Nuss

[Humpty-Dumpty]

Antwort auf Beitrag Nr.: 37.377.210 von HarteNuss am 12.06.09 00:21:44

eine sehr langfristige investition

[chinagerd]

Antwort auf Beitrag Nr.: 37.377.050 von pardon am 11.06.09 23:28:50

Das ist schon richtig, Kondom überziehen (lassen) wenn eine Erektion
da ist, aber, wie es manchmal so kommt, da verzieht sich langsam die
Steife und da hilft dieses neue Kondom. Soll ein stimulierender Wirk-
stoff drin sein, das ist ja das Patent !!! Na, dann auf zu ganz neuen
Gefühlen.

[zocklany]

eine Frau mit steifem Mund? das wär mir nix

[chinagerd]

Antwort auf Beitrag Nr.: 37.377.460 von zocklany am 12.06.09 07:21:55

Nun mal nicht anzüglich werden, ist eine ernsthafte Sache, oder???

[Bender04]

Ist der Deutsche Investment Report wieder am Start???

[greatmr]

Antwort auf Beitrag Nr.: 37.377.050 von pardon am 11.06.09 23:28:50

wahrscheinlich musst du erst mal locker reinhängen lassen

[Datteljongleur]

Antwort auf Beitrag Nr.: 37.377.050 von pardon am 11.06.09 23:28:50

War es nicht bisher eher so, daß man ein Kondom dann überzog, wenn man schon eine Erektion hatte?


Soweit ich das verstanden habe, musst du Dir dieses neuartige Kondom über den Kopf ziehen!!!

[1erhart]

Antwort auf Beitrag Nr.: 37.378.337 von Datteljongleur am 12.06.09 09:45:39

Ich frage mich immer nur wo du zu jeder Unterhaltung das passende Bild her hast. Wenn ich auch wie du weisst im Investmentbereich dir meistens nicht recht gebe aber das ganze mit diesen immer schönen, lustigen Bildern fasziniert mich immer wieder.

[Datteljongleur]

Antwort auf Beitrag Nr.: 37.378.354 von 1erhart am 12.06.09 09:47:30

Wenn ich auch wie du weisst im Investmentbereich dir meistens nicht recht gebe ...

Z.B.?

[BrauchGeld]

Diese äußerst attraktive Kaufkurse haben wir hauptsächlich der Krise zu verdanken einwenig Geldnot hatte die Firma auch das gehört aber der vergangenheit an !

Diese Aktie wird in keinem Börsenbrief oder sonst wo empfohlen und daher auch nicht ausgelutscht wie die meißten Biotechs .

Outlook

We are making good progress across our product portfolio whilst being very mindful of our resources and product priorities. We remain firmly on course to becoming a revenue generating business with a recurring royalty income stream from CSD500 and share our commercial partner’s belief that CSD500 is destined to become a highly successful product.


27 November 2008
Positive opinion on CSD500

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce that it has received positive regulatory opinion relating to the pharmaceutical aspects of CSD500, the Company's innovative condom to help men maintain a firm erection. The positive opinion marks the pivotal step towards European marketing authorisation for CSD500, which will be sold under the Durex® brand by SSL International plc (SSL).

The Competent Authority's opinion forms a key part of the process to permit the award of a CE Mark, the regulatory approval mechanism for this class of medical device in Europe. The award of the CE Mark will allow CSD500 to be marketed throughout all EU member states.

CSD500 will be manufactured, marketed and distributed by SSL under the Durex® brand.

To protect the unique intellectual property of CSD500, patents have been granted, or are proceeding to grant, in 32 consumer markets, including the key commercial territories in Europe and the US, and are pending in a further 4 territories.

James Barder, Futura's Chief Executive, said: "This positive regulatory opinion for CSD500 marks a pivotal step for Futura and we can now look forward to the award of the CE Mark and the product's commercial launch as a Durex® branded condom. This positive opinion highlights the quality of the Futura's technology and our project management, and gives us confidence in our regulatory approach to our portfolio of products."

Leigh Taylor, Head of Innovation at SSL, said: "CSD500 is a highly innovative solution that will improve the sexual well-being of millions of people. We look forward to seeing this product in the Durex® condom range."


Major Shareholders
(as at 1 April 2009)

Institutions holding more than 3% of the share capital of Futura were:

* Brookwell Ltd 6.60%
* Gartmore Investment Management 3.79%
* Fortis Investment Management 3.03%

Other shareholders holding more than 3% of the share capital of Futura were:

* RA Lamb 7.75%
* WT Lamb Investments Limited 6.83%
* Medinvest Holdings Limited 6.38%
* Christopher John Crabtree 5.51%
* Barclays Private Bank 3.13%

[greatmr]

Antwort auf Beitrag Nr.: 37.378.882 von BrauchGeld am 12.06.09 10:39:48

zumindest hast du sie heute schon mal 10% nach oben geprügelt - ist doch schon mal was

[BrauchGeld]

Antwort auf Beitrag Nr.: 37.378.994 von greatmr am 12.06.09 10:50:04

Ich will mit und nicht durch euch verdienen deshalb hab ich sie hier als erstes vorgestellt !



http://www.shortnews.de/start.cfm?id=678095


Zauberkondom macht Sex heißer, Penis größer und härter
Die Firma Futura Medical Plc wird im nächsten Jahr wohl ein Kondom auf den Markt bringen, welches selbst Kondom-Hasser vom Gegenteil überzeugen könnte. Das Kondom mache den Penis länger und härter, so das Unternehmen.

Verantwortlich für den längeren Penis ist ein Gel in der Spitze des Kondoms. Dieses sorgt dafür, dass sich die Arterien im Glied des Mannes weiten und somit der Blutfluss in den Penis gesteigert wird.

Das Kondom trägt den Namen "CSD500" und würde nach Erkenntnissen der Hersteller 80 Prozent der Kondomnutzer neugierig machen. Aber auch 49 Prozent der Kondom-Hasser würden das Produkt verwenden. Grund: die bessere Erektion.

[buschkuckuck]

Antwort auf Beitrag Nr.: 37.379.025 von BrauchGeld am 12.06.09 10:54:16

CSD 500

GTI 16 V mit Einspritzung, das wäre ein Name !

[Datteljongleur]

Antwort auf Beitrag Nr.: 37.378.994 von greatmr am 12.06.09 10:50:04

zumindest hast du sie heute schon mal 10% nach oben geprügelt -

Und das ganz ohne Umsatz!!!

[RebellSeaskip]

Hat doch was, wenn die Kurve nach oben zeigt ... *hust*

[buschkuckuck]

Futeral Medical

leicht zu merken

[chinagerd]

Antwort auf Beitrag Nr.: 37.379.025 von BrauchGeld am 12.06.09 10:54:16

Ja wenn das so ist, dann kann ich ja meine ganzen Viagra den Hähnen
geben, so daß die Hühner dann mehr Eier legen.

[RebellSeaskip]

Der Kurs hält sich standhaft

[BrauchGeld]

Antwort auf Beitrag Nr.: 37.382.058 von RebellSeaskip am 12.06.09 16:01:32

Ein bißchen geduld musst du mitbringen wirst dafür auch belohnt !!

[RebellSeaskip]

Antwort auf Beitrag Nr.: 37.382.105 von BrauchGeld am 12.06.09 16:05:04

Ich weiß, Frauen mögen das

[aufsicht]

Antwort auf Beitrag Nr.: 37.377.210 von HarteNuss am 12.06.09 00:21:44

ich kann schon verstehen, dass Du jetzt müde bist. Wie viele von den 10000 Stück hast Du schon verbraucht ?

[BrauchGeld]

Marktkap beträgt gerade mal 17 Mio € von hier aus kann es nur aufwärts gehen ,selbst drüben auf der Insel ist dieses Juwel kaum bekannt .

Kursexplosion wird kommen !


Director's Name - Ordinary Shares Purchased - March 2009

William Potter 50,000 20p
James Barder² 125,000 20p
Derek Martin 125,000 20p
David Davies 125,000 20p

James Barder, Futura's Chief Executive, said: 'I am delighted to announce this fundraising, which will provide additional working capital ahead of our anticipated transformation into a revenue generating and cash generative company through the launch by SSL International plc of our innovative condom, CSD500. My fellow Executive Directors and I are very pleased to have participated in this fundraising, which will allow us to support the development of our exciting product pipeline.'


http://fool.uk-wire.com/cgi-bin/index?search_type=3&words=FU…



Product updates


CSD500: Condom safety device

The highlight of 2008 for CSD500 came close to the year end with the positive regulatory opinion from the Competent Authority in the EU with respect to the pharmaceutical aspects of the product. This regulatory opinion marked the successful culmination of the clinical programme on CSD500. The Competent Authority confirmed that CSD500 is a Class III medical device with an ancillary medicinal substance.


As outlined above, the logical restructuring of SSL's global manufacturing base means that additional manufacturing data is required as part of the CE mark application, as the product will now be manufactured in Asia rather than in Europe. This work is already well underway and it is expected that CE marketing authorisation will be received around the end of the current year with the launch of CSD500 as soon as possible thereafter. We have no requirement to carry out further clinical work on CSD500.


In our 2007 annual report, we highlighted the successful outcome of a user study involving 108 couples in which CSD500 successfully met its endpoints of demonstrating the maintenance of a firmer erection in healthy men during sex and increased penile size and a longer lasting sexual experience.


In addition to positive clinical data, the results of our previously commissioned market research reinforce the commercial potential of CSD500. The market research, conducted by an internationally recognised research company, showed that 88% of existing condom users would be interested in purchasing CSD500 and that 49% of non-condom users would be interested in purchasing the product. The research also showed that 46% of men had experienced some loss of sensitivity when using a condom during sexual intercourse, which can lead to loss of erection. This is one reason why some men avoid condoms, thereby increasing the risks of unwanted pregnancies and contracting or spreading sexually transmitted infections ('STIs').


As supported by our market research we believe that CSD500 will have a strong appeal to men and women who already use condoms as well as men and women who do not currently use them.


STIs are a serious and growing problem. In the UK, a Government report from the Health Protection Agency¹, published in 2007, indicated that in the previous 10 years new cases of syphilis had increased by 1130%, HIV by over 300%, gonorrhea by 45% and chlamydia by 166%.


We have protected CSD500's unique intellectual property position throughout the world including the principal consumer markets within Europe, the US and Canada through patents now granted or proceeding to grant in 33 countries and applications pending in a further 3.


MED2002: Treatment for erectile dysfunction, and FLD500: Female lubrication device

MED2002, our topical gel for the treatment of men with erectile dysfunction, is also licensed to SSL and has the potential to become the world's first non-prescription pharmaceutical treatment for men with erectile dysfunction, a condition that affects, to some degree, as many as 52% of men aged 40 or over2.


CSD500 and MED2002 are somewhat interdependent as they share the same active compound. To a large extent, the positioning of MED2002 in the market place, and the final details of the regulatory strategy, will depend upon SSL's and our experience following the launch of CSD500. It has therefore been agreed between us to prioritise resources towards launching CSD500 as soon as possible.


FLD500, a condom-based product designed to improve natural female lubrication during sexual intercourse, uses the same active compound as CSD500 but in FLD500 the active compound is on the outside of the condom so that it is rapidly absorbed through the vaginal mucosa during sexual intercourse. For FLD500, as with MED2002, the final marketing positioning and regulatory strategy will depend upon our experience in the launch of CSD500. With 40% of condoms being purchased by women we firmly believe that a female version of CSD500 would have considerable consumer appeal. The precise regulatory pathway and route to market will be determined with our commercial partner in due course.


TPR100: Topical pain relief

TPR100 leverages one of our key proprietary assets, DermaSys®, a highly efficient, transdermal delivery system, which facilitates rapid absorption of pharmacologically active ingredients through the skin. In TPR100 we are using DermaSys® for the topical delivery of a non-steroidal anti-inflammatory drug ('NSAID') for pain relief.


During the year we optimised the formulation and dose of the NSAID molecule and have recorded skin permeation rates between 30 to 40 times higher than that achieved by the market-leading product. Furthermore oral NSAID products are associated with side effects due to high systemic drug levels, therefore we feel there is a clear market opportunity for a faster acting topical formulation.


Following consultations with the relevant regulatory authorities we believe the regulatory pathway for TPR100 is relatively straightforward as the active compound is well characterised and has already been approved in both oral and topical form for the indication of pain relief. The minimum requirements to satisfy EU regulators are likely to comprise a Phase I trial of around 24 healthy volunteers to demonstrate a lack of skin irritation or sensitisation followed by a pivotal Phase III trial of around 250 subjects to demonstrate non-inferiority to a market-leading product in the treatment of pain secondary to osteoarthritis in the knee.


Based on our research and development programme so far we remain confident of a positive outcome to these studies, which we expect will be funded by our commercial partners. For this reason we do not intend to begin these trials prior to out-licensing TPR100. Commercial discussions continue with respect to the out-licensing of the product, either on a global or regional basis, and we look forward to updating our shareholders in due course.



PET500: Premature ejaculation treatment

Significant progress was made during the year with PET500, our premature ejaculation treatment which combines our DermaSys® delivery system with a well known mild topical anaesthetic compound. In December 2008 we announced positive results from a Phase I clinical study of 20 healthy volunteers in which PET500 was shown to give a rapid and controlled reduction in penile sensitivity, thereby having the potential to prevent premature ejaculation. No adverse events were recorded in the study.


PET500's formulation is designed to delay ejaculation for a period of approximately 8 minutes, after which time the effect of the mild anaesthetic dissipates. The Phase I study met all endpoints, which were devised following consultation with a number of leading medical experts in the field of premature ejaculation and on the basis of qualitative market research in patients.


We are currently awaiting feedback from the relevant regulatory authorities before deciding on the regulatory positioning of PET500. Our preference is to develop a product that reduces penile sensitivity to help those men who suffer from early ejaculation who would like to prolong the sexual experience with their partner. The regulatory positioning of the product will determine our commercial strategy though we are already in discussions with several parties.


RAD100: Rapid anaesthetic delivery

This is a new gel under development which provides rapid local anaesthesia prior to injections. The impressive results seen in our Phase I study of PET500, which used a low dose of the same active ingredient, prompted us to explore the potential of the same concept at a much higher dose to provide rapid topical anaesthesia prior to injections, vaccinations and cannulations. Demand in this market is already well developed but poorly served with treatments taking at least 30 to 45 minutes to take effect. We believe there is clear commercial potential for a product in which the speed of onset of skin desensitisation is significantly faster.


In early clinical work already completed, we have shown a 250% increase in the rate of permeation of a topical anaesthetic across the skin using RAD100 and the DermaSys® delivery system when compared to a market leading product. This substantial increase in skin permeation is expected to equate to a more rapid onset of skin desensitisation compared to existing products.


RAD100 has already attracted interest from commercial partners and we are in commercial discussions for this product.


DermaSys®

In response to the technical challenge of formulating PET500, we expanded our DermaSys® delivery technology platform by designing a unique non-aqueous carrier, DermaSys® AquaFree. This new system, which incorporates the benefits of our existing DermaSys® technology, provides the potential for hydrolytically unstable (i.e. water-sensitive) drugs to be developed into commercially attractive topical products.


People

We have continued to run a highly efficient business with a focus on cost control. Staff numbers (including non-executive directors) were 10 at the year end, compared with 14 at 31 December 2007. We would like to offer our sincere thanks to all of our staff and scientific advisers for their dedication and commitment throughout the year.


Outlook

We are making good progress across our product portfolio whilst being very mindful of our resources and product priorities. We remain firmly on course to becoming a revenue generating business with a recurring royalty income stream from CSD500 and share our commercial partner's belief that CSD500 is destined to become a highly successful product.

[BrauchGeld]

A CONDOM that enlarges todgers AND makes fellas last longer in bed has been developed.

The rubber works like Viagra ? but also protects against sexually transmitted infections.

A powerful gel in the condom is absorbed through the skin and opens arteries, boosting blood flow and making the penis enlarge and stay erect.

The super-sheath has been developed by UK firm Futura Medical under the lab name CSD500.

It will be marketed by Durex under another name, and is due to hit the market later this year.

Doctors hope it will encourage thousands more men to use condoms ? the only protection against Chlamydia and HIV which can leads to Aids.

Britain is currently facing its highest ever level of Aids infections, while one in ten women has Chlamydia ? which can cause infertility.

In the latest trials, 108 healthy couples tried the condom.

They said it helped men get firmer erections compared with standard condoms, and made sex last longer. Futura boss James Barder said: “We expect to get regulatory EU approval later this year.

“Research has shown so far that interest in the condom is enormous.”

The Family Planning Association said yesterday: “Condoms are the only form of contraception that protect against STIs and unplanned pregnancy.”

[BrauchGeld]

Kurs : 24p = 0,285€

15:23 24.30p 60,000 £14,580 Buy O
15:23 24.50p 60,000 £14,700 Buy O
13:47 24.25p 4,062 £985 Buy O
10:48 23.55p 1,716 £404 Sell O
09:06 23.55p 2,536 £597 Sell O

[EvertonFC]

Antwort auf Beitrag Nr.: 37.404.893 von BrauchGeld am 16.06.09 19:03:52

Hallo Brauchgeld

Ich habe versucht herauszufinden welche Höhe die Lizenzzahlungen von Durex ausmachen könnten.

SSL (Durex) hat einen Jahresumsatz von knapp 700 Mio. Euro.

Ich habe keine Details über die prozentuale Beteiligung von Futura Pharma finden können. In welcher Grössenordnung könnten die Lizenzzahlungen prozentual liegen?

[BrauchGeld]

Antwort auf Beitrag Nr.: 37.420.774 von EvertonFC am 18.06.09 17:37:36

Hallo Everton

Futura erhält 15% vom Gewinn !

[GARDER]

Antwort auf Beitrag Nr.: 37.420.948 von BrauchGeld am 18.06.09 17:51:01

Dann ist der Gewinn der bei Futura hängen bleibt ziemlich klein!

Wenn Durax gerademal einen Umsatz von 700 Millionen hat, kann beim Gewinn nicht viel übrig bleiben. Bei einer Rendite von z.B. 10% bleiben gerademal 70 Millionen Gewinn. Die 70 Millionen stzten sich sich aber aus allen Produkten des Sortiments! Wenn das neue Kondom vielleicht ein Drittel dazu beiträgt (was sehr hoch angestzt wäre), bleiben für Futura lediglich 3 Millionen!

Liege ich da falsch....

[EvertonFC]

Antwort auf Beitrag Nr.: 37.437.360 von GARDER am 22.06.09 00:01:28

.....und das kann eben nicht sein.

Solche Beteiligungen beziehen sich immer auf den Umsatz und nicht auf den Gewinn, den der Lizenznehmer erzielt. Der hängt von ganz anderen Faktoren ab und ist nicht Grundlage eines Lizenzabkommens.

Ich habe auch leider noch keine Bestätigung der Zahl 15% durch Brauchgeld trotz Bitte um einen Link per BM.

Aus den 700 Mio Umsatz den Durex im Moment erzielt würde ich keine Schlüsse auf den möglichen Umsatz und damit Erfolg dieses neuen Kondoms ziehen.

[BrauchGeld]

Antwort auf Beitrag Nr.: 37.437.389 von EvertonFC am 22.06.09 00:24:30

Hallo Everton

Sorry das es etwas gedauert hat war in Urlaub und hatte kaum gelegenheit ins Netz zukommen !

Ja stimmt hab mich vertan natürlich 15% vom Umsatz ,leider kann ich den Text nicht kopieren (gesperrt) du musst dich bei Edison anmelden (ist kostenlos) um diese Analysen lesen zukönnen .

http://www.edisoninvestmentresearch.co.uk/search/results/b75…


Futura Medical hat einen jährlichen Cashburn von gerade mal rund 2,5 Mio€ es braucht also nicht viel um in die Profitabilität zu gelangen .

2 Deals sind noch für dieses Jahr geplant und schon anfang 2010 wird das Superkondom erhältlich sein .

Also viel falsch kann man hier nicht falsch machen !

[BrauchGeld]

Antwort auf Beitrag Nr.: 37.480.195 von BrauchGeld am 27.06.09 17:20:03

Also viel falsch kann man hier nicht falsch machen ! hört sich gut an

[BrauchGeld]

Gute Nachrichten ....Erster Deal fast abgeschlossen !

For immediate release 20 July 2009

Futura Medical plc

("Futura" or "the Company")

Evaluation agreement for the development and commercialisation of TPR100

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce that it has signed an evaluation agreement with a major pharmaceutical company in connection with the development and commercialisation of TPR100, a novel, topically applied product for pain relief.

Futura will receive an upfront £50,000 payment from the major pharmaceutical company, which intends to carry out further in vitro studies on TPR100 during the evaluation period.

The evaluation period, which will commence immediately and continue until later this year, may, or may not, result in a commercialisation agreement for rights to TPR100 in certain territories.

The active ingredient in TPR100 is a well characterised non-steroidal anti-inflammatory drug ("NSAID") and it is delivered through the skin by Futura's DermaSys® technology, a highly efficient trans-dermal delivery system that facilitates rapid absorption.

Clinical tests have shown that TPR100, which is designed to be an over-the-counter product, achieves skin permeation rates between 30 to 40 times higher than that achieved by the current market-leading product. TPR100's rapid absorption brings potential benefits including a more rapid onset of action of pain relief.

James Barder, Futura's Chief Executive, said: "This evaluation agreement with a major pharmaceutical company reflects the solid progress we have made to date on the development of TPR100, our fast-acting, topically applied pain relief product. The evaluation agreement follows a period of detailed due diligence by the major pharmaceutical company and we are hopeful that ultimately it will result in the commercialisation of the product whilst the modest payment will meet key patent filing costs associated with TPR100 due shortly."

[BrauchGeld]

Hab nochmal 10000st nachgelegt ...

[BrauchGeld]

Wer einsteigen will sollte es jetzt tun viel billiger wird die Aktie nicht mehr .

[EvertonFC]

Antwort auf Beitrag Nr.: 37.620.343 von BrauchGeld am 22.07.09 10:05:42

Bis zur Vermarktung des Kondoms kann es noch etwas dauern, wenn ich es richtig erinnere. Man bereitet derzeit die Produktion vor, Vermarktung und Verkauf sollen jedoch erst Anfang nächsten Jahres beginnen?? Gibt es deiner Meinung nach einen anderen Near Tern Katalysator?

[dottore]

Antwort auf Beitrag Nr.: 37.387.477 von BrauchGeld am 13.06.09 19:36:04

William Potter kauft die Aktie als Insider. Schließlich kommt das Zauberkondom aus der Schulke seines Sohnes Harry

[dottore]

Antwort auf Beitrag Nr.: 37.437.360 von GARDER am 22.06.09 00:01:28

bei 3 Mio Gewinn und 17 Mio Marktkapitalisierung wäre das doch bombastisch! Aber 3 Mio ist viel zu hoch gegriffen. Man darf da von 500 000 € ausgehen.

[BrauchGeld]

Antwort auf Beitrag Nr.: 37.623.759 von EvertonFC am 22.07.09 16:02:42

Gibt es deiner Meinung nach einen anderen Near Tern Katalysator?

Der gestrige Deal ist noch nicht abgeschlossen ,sollte sich das Pharma für TPR100 entscheiden gibts flocken für Futura spätestens ende des Jahres wissen wir mehr .

The evaluation period, which will commence immediately and continue until later this year, may, or may not, result in a commercialisation agreement for rights to TPR100 in certain territories.

Weitere Deals sind noch für dieses Jahr geplant und möglicherweise wird Futura übernommen ,es bleibt spannend ..


@dottore

Geh woanders spielen ...

[dottore]

Antwort auf Beitrag Nr.: 37.624.998 von BrauchGeld am 22.07.09 18:03:34

also "Brauchgeld", bleib mal auf dem Teppich. Auch wenn du eine Reihe Biotechs ausgegraben hast und gute Kurssteigerungen kamen, so sieht man auch, dass die Mehrheit deiner Ausgrabungen schon wieder verschollen sind.
Und der Kurs dieser Aktie scheint sich langsam aber sicher auch zu verabschieden. Deinen Schnitt wirst du wohl gemacht haben. Alle anderen warten auf bessere Zeiten bis sie aufgeben ....

[BrauchGeld]

Antwort auf Beitrag Nr.: 37.667.923 von dottore am 29.07.09 11:15:25

@dottore

Und der Kurs dieser Aktie scheint sich langsam aber sicher auch zu verabschieden.

Was schreibst du für´n Müll ?? Der Kurs ist stabil und ich bin immer noch dabei so schnell werde ich diese Perle nicht verkaufen vor allem nicht wenn in kürze sehr gute Nachrichten zu erwarten sind .

Es gibt im Augenblick nichts zu berichten das ist alles !!

[BrauchGeld]

Futura´s tag wird kommen ...

Fact Sheet :: Alle Daten auf einen Blick

http://www.futuramedical.co.uk/pdf/investors_fact_sheet.pdf


Strong Buys
BTG, Vectura Group, Antisoma, Goldshield Group, GW Pharmaceuticals, China Medical System Holdings, Hutchison China Meditech, Asterand, IS Pharma, EpiStem Holdings, Alliance Pharma, ReNeuron, Avacta Group, Source BioScience, Futura Medical, Phytopharm, Summit Corporation, Allergy Therapeutics

Buys
Hikma Pharmaceuticals, Dechra Pharmaceuticals, ProStrakan, Immupharma, Oxford Biomedica, Puricore

[dottore]

Antwort auf Beitrag Nr.: 37.693.924 von BrauchGeld am 02.08.09 11:29:16

das hin und her, so richtig aufwärts gehts nu doch nicht.

was hälst du von Caraco Pharm?

[BrauchGeld]

Was Potential und Unterbewertung angeht ist Futura unter den UK-Biotechs so das beste was man an der LSE bekommen kann !


http://www.growthcompany.co.uk/features/1063792/time-to-bag-…

Time to bag biotech bargains

Swine flu profits should encourage Big Pharma to ‘take more risks on investing in biotech’

03/08/2009 Oliver Haill

Massive markets

Futura Medical fans have looked to Pfizer’s successful journey on the back of its famous blue pill as an illustration of the huge global potential for its own product for a similar market. In partnership with Durex condom-maker SSL, Futura will trust that its CSD 500 erection-maintaining condom can grab some of this considerable demand, though investors have felt less stimulated by prospects lately, with the shares having fallen from a 45.5p year high to 24p.

--------------------------

Futura strikes evaluation pact

Drug developer Futura Medical says a ‘major pharmaceutical company’ is to consider commercialising its TPR100 pain relief cream.

The Guildford-based company, whose lead product is the CSD 500 erection-maintaining condom, says the unnamed big group has agreed to pay an initial £50,000 to carry out two studies to enable it to evaluate TPR100, whose initials stand for ‘topical pain relief’, designed as an over-the-counter product for fast-working alleviation. If the evaluation goes well, Futura’s potential partner will then decide whether to enter into an agreement to commercialise TPR100, which is described as a ‘non-steroidal anti-inflammatory drug’.

AIM-quoted Futura says clinical tests have shown that TPR100 permeates patients’ skins 30 to 40 times more thoroughly than current market-leading products. Chief executive James Barder says this evaluation agreement reflects ‘solid progress’ made developing TPR100, arguing that it follows a period of ‘detailed due diligence’ by the other party.

Futura, which lost £2 million last year, ended 2008 with £780,000 cash and raised another £1 million in March at 20p. The shares, tipped here at 27.5p last November, have swung between 45.5p and 12p over the past year. At the current 24.25p, valuing the company at a shade over £15 million, they could move higher if the evaluation leads to a deal.

[GARDER]

Futura, which lost £2 million last year, ended 2008 with £780,000 cash and raised another £1 million in March at 20p. The shares, tipped here at 27.5p last November, have swung between 45.5p and 12p over the past year. At the current 24.25p, valuing the company at a shade over £15 million, they could move higher if the evaluation leads to a deal.


Naja finanziell ist das ja nicht so doll gestellt. Noch so ein Jahr wie 2008 und die Firma ist pleite. Ich lasse die Finger davon. Man da immer noch einsteigen, wenn sich die Gewinnsituation aufhellt. Ich verzichte lieber auf die ersten Zockerprozente und kaufe dann bei "fast sicheren" bei höheren Kursen.

[BrauchGeld]

Antwort auf Beitrag Nr.: 37.752.756 von GARDER am 11.08.09 12:09:55

Ich verzichte lieber auf die ersten Zockerprozente und kaufe dann bei "fast sicheren" bei höheren Kursen.

Du vergisst die Deals und das Futura so gut wie keine Ausgaben mehr hat !! Also ein Zock sieht für mich anders aus ..

[BrauchGeld]

Good news !!!!

Die Zulassung wird für ende des Jahres erwartet und Markteinführung soll kurze Zeit später folgen !!!


For immediate release


8 September 2009



Futura Medical plc


Update on CSD500


Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce that CSD500, its lead product to be launched as a Durex®-branded condom by SSL International plc (SSL), is on track to receive the CE Mark following the transfer of manufacturing by SSL to facilities in India.


Futura and SSL had initially provided the relevant Notified Body and Competent Authority - the regulatory bodies overseeing the award of the CE Mark - with technical data relating to the manufacture of CSD500 in Spain. Following the move of manufacturing to India it is a normal regulatory requirement to undertake validation runs at the new location. The validation runs have now been undertaken and data on manufactured product is being generated according to a pre-defined schedule to demonstrate compliance with specification and thereby to satisfy the remaining regulatory requirements.


Discussions are now underway with the relevant Notified Body to agree the schedule for the granting of the CE Mark, the European marketing authorisation for the product.


The timing of the grant of the CE Mark for CSD500 remains in line with earlier estimates of around the end of the current calendar year with commercial launch by SSL thereafter.


James Barder, Futura's Chief Executive, said: 'I am pleased by the progress that has been made following the enormous effort put in by the technical teams to complete this transfer as quickly as possible and move to commercialisation.'

[BrauchGeld]

Es scheint endlich los zugehen .. Für mich ist Futura eine Win-win-Situation !!!

[BrauchGeld]

Die Zahlen sind da und bisher läuft alles nach plan !!!

http://www.futuramedical.co.uk/archive/interim_report_2009.p…


23 September 2009
Interim Results for the six months to 30 June 2009

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce its Interim Results for the six months to 30 June 2009.
Highlights

* Five products currently in development, comprising both medical devices and pharmaceuticals predominantly focused on the over the counter market
* CSD500 - Completion of manufacturing data progressing prior to European marketing authorisation
* PET500 - Positioning of enhanced sexual control means a shorter regulatory process and potential for early launch in the USA subject to finalisation of a commercial agreement
* TPR100 - Evaluation agreement signed in July 2009 with major pharmaceutical company
* Pre-tax loss of £0.7 million for the six months ended 30 June 2009 (H1 2008: Pre-tax loss of £1.1 million)
* Cash of £1 million at 30 June 2009 (31 December 2008: £0.8 million)

James Barder, Futura Medical's Chief Executive, said: "Progress to date in 2009 continues to reinforce our confidence in the future. CE mark approval for CSD500 is anticipated around the end of the year. We are also excited by the rapid progress on PET500, and on progress elsewhere in our pipeline of opportunities."

[BrauchGeld]

Es liegt so ein angenehm süsslicher geruch in der Luft ahh das ist der duft der €-Noten die bald in mein Depot fließen werden!!!

Futura nears product launch

23/09/2009 Robert Tyerman


Futura Medical is awaiting regulatory approval before the launch of its Durex-branded condom with partner SSL International
Futura Medical is awaiting regulatory approval before the launch of its Durex-branded condom with partner SSL International

Loss-making Futura Medical expects marketing authorisation for its CSD 500 erection-maintaining condom ‘around the end of the year’.

The Guildford-based company, which is developing five products in the consumer healthcare market, reduced its losses 34 per cent to £706,000 in the six months to June. Chief executive James Barder says AIM-quoted Futura, which ended the half year with £965,000 cash, is ‘on course’ to win marketing authorisation for CDS 5000 in a few months.

This would pave the way for the launch of the product with Futura’s partner, Durex maker SSL International, as a ‘Durex-branded condom'. Meanwhile, Barder says he is in discussions 'with several potential commercial partners' since the company modified the formulation of its PET5000 sexual ejaculation delaying spray to comply with the requirements of the US Food and Drugs Administration.

[BrauchGeld]

Bald ist es vorbei mit den billigen Kursen !!!!!

[BrauchGeld]

Bye bye 30p

[BrauchGeld]

Antwort auf Beitrag Nr.: 38.084.182 von BrauchGeld am 30.09.09 11:25:00

Das sieht herrlich aus !!!

[BrauchGeld]

Aktuell 37p = ~ 0,41 € macht ca 24 Mio€ Marktkap was immer noch sehr attraktiv ist ...

[BrauchGeld]

Antwort auf Beitrag Nr.: 38.093.565 von BrauchGeld am 01.10.09 12:06:09

In 2009 ist mit der EU-Zulassung und weitere Partnerdeals zurechnen das dürfte uns locker über 1€ bringen..

[BrauchGeld]

iii-board ist ziemlich aktiv falls einer reinschauen will...
http://www.iii.co.uk/investment/detail?code=cotn:FUM.L&displ…

und alle News zu Futura findet man hier ..
http://fool.uk-wire.com/cgi-bin/index?search_type=3&words=FU…

[BrauchGeld]

Es gab vor ein paar Tagen ein neues Buy-Rating mit Kursziel 120p !

Die Zulassung müsste in den nächsten Tagen kommen ...

[BrauchGeld]

Die Zulassung ist schon eine fast sichere Sache und die Aktie ist immer noch Saubillig ...

[Eclipse_71]

Was ist mit der Aktie los?

[BrauchGeld]

Alles läuft wunderbar für Futura , Markteinführung für das Superkondom bleibt zwischen 2Q-3Q 2010 .

Marktkap ist nach wie vor sehr niedrig mit 26,5 Mio€ .

Futura bewegt sich wieder richtung Jahreshoch .

# PROGRESS TOWARDS THE MARKETING AUTHORISATION OF ITS LEAD PRODUCT, CSD500, WHICH IS SCHEDULED TO BE LAUNCHED AS A DUREX (R)-BRANDED CONDOM BY SSL INTERNATIONAL PLC

# GENERATION OF DATA REQUIRED TO COMPLETE THE CE MARK APPROVAL PROCESS
continues as planned

# A NUMBER OF POTENTIAL IMPROVEMENTS TO THE MANUFACTURING PROCESS HAVE BEEN
identified

# EXPECTS SSL TO FILE THE ADDITIONAL DATA FOR CE MARK APPROVAL EARLY IN THE
first quarter of 2010

# SUBJECT TO TIMELY CE MARK APPROVAL, CSD500 REMAINS ON COURSE TO BE LAUNCHED
later in 2010